Similar articles for PMID: 29277814

Year	Number of Results
2008	1
2009	4
2010	6
2011	4
2012	6
2013	5
2014	10
2015	23
2016	15
2017	10
2018	10
2019	8
2020	5
2021	6
2022	5
2023	1
2024	0

1

Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.

Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H. Miyamoto Y, et al. Anticancer Res. 2018 Jan;38(1):491-499. doi: 10.21873/anticanres.12249. Anticancer Res. 2018. PMID: 29277814

2

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.

Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, Krausé D, Hillon P, Borg C, Chauffert B, Ghiringhelli F. Guiu B, et al. Gut. 2010 Mar;59(3):341-7. doi: 10.1136/gut.2009.188946. Epub 2009 Oct 15. Gut. 2010. PMID: 19837679

3

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. Hanna DL, et al. Clin Colorectal Cancer. 2018 Sep;17(3):e471-e488. doi: 10.1016/j.clcc.2018.03.006. Epub 2018 Mar 14. Clin Colorectal Cancer. 2018. PMID: 29636300 Free PMC article.

4

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY. Tsai HL, et al. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973082 Free PMC article.

5

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.

Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Yamamoto S, et al. BMC Cancer. 2021 Oct 29;21(1):1159. doi: 10.1186/s12885-021-08890-6. BMC Cancer. 2021. PMID: 34715820 Free PMC article.

6

Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.

Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandroni P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F. Catalano V, et al. J Cancer Res Clin Oncol. 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w. Epub 2019 Nov 6. J Cancer Res Clin Oncol. 2020. PMID: 31691872

7

[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J. Cabart M, et al. Bull Cancer. 2016 Jun;103(6):541-51. doi: 10.1016/j.bulcan.2016.03.007. Epub 2016 May 5. Bull Cancer. 2016. PMID: 27155924 French.

8

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.

Bazarbashi S, Aljubran A, Alzahrani A, Mohieldin A, Soudy H, Shoukri M. Bazarbashi S, et al. Cancer Med. 2015 Oct;4(10):1505-13. doi: 10.1002/cam4.497. Epub 2015 Jul 24. Cancer Med. 2015. PMID: 26207614 Free PMC article. Clinical Trial.

9

Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.

Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Formica V, et al. Cancer Biomark. 2009;5(4):167-75. doi: 10.3233/CBM-2009-0101. Cancer Biomark. 2009. PMID: 19729826

10

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Hegewisch-Becker S, et al. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361971 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year